Glenmark receives US FDA approval for Icatibant Injection :

Glenmark receives US FDA approval for Icatibant Injection
Glenmark receives US FDA approval for Icatibant Injection
25 May 2021 | News
The injection will be manufactured in their North American manufacturing facility based in Monroe, North Carolina
Glenmark Pharmaceuticals (Glenmark) has received final approval by the United States Food & Drug Administration (US FDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr 1 Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies. This marks Glenmark's first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.

Related Keywords

United States , North Carolina , American , , Glenmark Pharmaceuticals , United States Food Drug Administration , United States Food , Drug Administration , Icatibant Injection , Single Dose Prefilled Syringe , Shire Human Genetic , North American , Firazyr Injection , Glenmark , S Fda , ஒன்றுபட்டது மாநிலங்களில் , வடக்கு கரோலினா , அமெரிக்கன் , க்ளேண்மர்க் மருந்துகள் , ஒன்றுபட்டது மாநிலங்களில் உணவு , ஶைர் மனிதன் ஜெநெடிக் , வடக்கு அமெரிக்கன் , க்ளேண்மர்க் ,